Viscosupplementation Market size to exceed $5.3 Bn by 2026
Published Date: June 16, 2020 Authors: Sumant Ugalmugle, Rupali Swain
Viscosupplementation Market size is estimated to surpass USD 5.3 billion by 2026; according to a new research report by Global Market Insights, Inc.
Increasing preference for single injection treatment of osteoarthritis will positively impact the market growth in the upcoming years. Owing to the factors such as growing elderly population susceptible to osteoarthritis and rising demand for minimally invasive treatments, the viscosupplementation market will witness significant growth over the forecast period. Moreover, companies focusing on the introduction of new products for the treatment of arthritis will enhance the market growth.
Presence of large patient pool suffering from osteoarthritis across the globe will bolster the market growth in the coming years
The economic burden of arthritis on the patients and society is high across the world. Rising incidences of osteoarthritis among geriatric population is one of the major factor driving the market growth.
Moreover, increasing focus of industry players towards the launch of new products coupled with rising preference for single injection viscosupplementation treatment will boost the market growth. For instance, in December 2019, Fidia Farmaceutici S.p.A. launched TRILURON (sodium hyaluronate) in the U.S. This viscosupplement is intended for the treatment of pain in osteoarthritis of knee. Thus, such product launches will offer lucrative potential for the market growth in the projected years.
Get more details on this report - Request Free Sample PDF
Browse key industry insights spread across 150 pages with 182 market data tables & 14 figures & charts from the report, “Viscosupplementation Market Size By Product (Single Injection, 3 Injections, 5 Injections), By Source of Origin (Avian Origin, Non-avian Origin), By End-use (Hospitals, Ambulatory Surgical Centers), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2026” in detail along with the table of contents:
Increasing preference for single injection viscosupplements over other treatments will enhance the segmental growth
The single injection segment was valued at around USD 1 billion in 2019 and is expected to showcase considerable market growth over the analysis period. The viscosupplementation market growth is attributed to the increasing inclination of the patients towards single injection viscosupplementation treatment. This shift of patients towards single injection treatment is stimulating the market players to manufacture viscosupplements with single injection.
Several advantages of viscosupplements with avian origin will impel the segmental growth
The avian origin segment held around 24% of viscosupplementation market share in 2019. The exogenous hyaluronic acid produced from avian origin includes poultry material such as cock crest. The viscosupplementation treatment with avian origin presents allergenic potential due to avian antigens. Such viscosupplements improves lubrication and reduces the mechanical overload on the joint.
Rising demand for minimally invasive treatments coupled with growing number of ambulatory surgical centers will enhance the segmental growth
The ambulatory surgical centers segment was valued at around USD 740 million in 2019 and is anticipated to register significant growth over the analysis period. Increasing number of ambulatory surgical centers across the globe and rising demand for minimally invasive treatments are the major factors driving the segmental growth. Hence, patients suffering from osteoarthritis will contribute to the increasing footfalls in ambulatory surgical centers thereby, fostering the market growth.
Strong presence of market players and high incidences of osteoarthritis across the country will impel the market growth during the forecast period
Germany dominated Europe viscosupplementation market share in 2019 and is projected to expand at a CAGR of 9.8% over the analysis period. The country growth is mainly attributed to the increasing number of people suffering from osteoarthritis. Thus, such large group of patients facing problems associated with joints will require the viscosupplementation treatment thereby, enhancing the market growth in Germany. In addition to that, growing geriatric population across the country will significantly contribute to the market growth over the forecast timeframe.
Japan viscosupplementation industry was valued at over USD 318 million in 2019 and is estimated to grow at a steady rate over the projected years. Owing to the presence of market players such as Chugai Pharmaceutical Co., Ltd and SEIKAGAKU CORPORATION, the country will witness substantial growth over the forecast period. Moreover, high prevalence of knee osteoarthritis and lumbar spondylosis in the Japanese population will positively influence the market growth. Additionally, increasing awareness regarding the effectiveness of viscosupplementation treatments and alternatives to avoid knee replacement surgeries will drive the country growth in the upcoming years.
Companies focusing on strategic acquisitions and new product launches will positively influence the market growth
Some of the prominent players in the viscosupplementation market share are Anika Therapeutics, Inc., Aptissen, Bioventus, Fidia Farmaceutici S.p.A., Johnson & Johnson Services, Inc., Mylan Inc., Zimmer Biomet, Wellchem Pharmaceuticals Pte Ltd. and Genzyme Corporation among others. These industry players are majorly focusing on various strategies such as partnerships, new product launches, mergers, acquisitions, and collaborations. For instance, in March 2019, SEIKAGAKU CORPORATION launched a new intra-articular single-injection viscosupplement called HyLink to treat the patients suffering from osteoarthritis in Italy. The strategic move helped the company to attract new customers thereby, enhancing its revenue growth.